On the other hand, NIC treatment at a dose of 7.5 mg/kg markedly reduced these fibrosis markers; TGF-β1 levels, HYP content, and COL1α1 expression by 54.75%, 46.52%, and by 35.09%, respectively, relative to the TAA-induced liver fibrosis group. The gene discussed is TGFB1; the disease is fibrosis.